MMP2 Antibody (YA3704)

MMP-2 (matrix metalloproteinase-2), also known as gelatinase A, is a zinc-dependent extracellular endopeptidase that plays a central role in extracellular matrix remodeling through the degradation of gelatin, type IV collagen, and other basement membrane components^[6][7]. Mechanistically, MMP-2 is synthesized as a latent proenzyme and is activated at the cell surface through the MT1-MMP/TIMP-2/pro-MMP-2 activation complex, linking its proteolytic activity to tightly regulated pericellular signaling and matrix turnover^[1][2]. Through these functions, MMP-2 contributes to cell migration, tissue remodeling, angiogenesis, and inflammatory regulation, making it an important mediator of both physiological repair processes and pathological tissue remodeling^[6][7]. Dysregulated MMP-2 expression or activation has been associated with cancer progression, cardiovascular disorders, kidney disease, diabetic complications, and fibrotic conditions, where excessive extracellular matrix degradation promotes disease development and tissue dysfunction^[6]. In tumor models, elevated MMP-2 activity correlates with invasive behavior, metastatic dissemination, and angiogenic remodeling, supporting its widespread use as a biomarker and mechanistic target in cancer research^[3][4]. Compared with the closely related gelatinase MMP-9, MMP-2 is constitutively expressed in many tissues and is preferentially regulated through MT1-MMP- and TIMP-2-dependent activation mechanisms, whereas MMP-9 is more commonly induced by inflammatory stimuli and exhibits distinct substrate and regulatory profiles^[7]. For experimental applications, broad-spectrum metalloproteinase inhibitors such as batimastat have been widely used to investigate MMP-2-dependent signaling and matrix remodeling, although selective targeting remains an active area of therapeutic development^[5].